Activity of fosfomycin and comparison of several susceptibility testing methods against contemporary urine isolates

2015/10/02 by Elizabeth B. Hirsch, Brian R. Raux, Paola Zucchi +6 · 27 citations
Medicine · Immunology and Microbiology · #Urinary Tract Infections Management #Bladder and Urothelial Cancer Treatments #Reproductive tract infections research

paper · doi:10.1016/j.ijantimicag.2015.08.012

Cited by

• Heteroresistance associated with the production of fosfomycin-resistant inner colonies during disk diffusion testing among a geographically diverse collection of Klebsiella pneumoniae clinical isolates
• Potential of fosfomycin in treating multidrug‐resistant infections in children
• Susceptibility of Multidrug-Resistant Gram-Negative Urine Isolates to Oral Antibiotics. [europepmc]
• Fosfomycin: Resurgence of an old companion. [europepmc]
• Fosfomycin and Comparator Activity Against Select Enterobacteriaceae, Pseudomonas, and Enterococcus Urinary Tract Infection Isolates from the United States in 2012. [europepmc]
• Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal fosA Gene. [europepmc]
• Fosfomycin Susceptibility in Multidrug-Resistant Enterobacteriaceae Species and Vancomycin-Resistant Enterococci Urinary Isolates. [europepmc]
• Mutual potentiation drives synergy between trimethoprim and sulfamethoxazole. [europepmc]
• Rapid Detection of Fosfomycin Resistance in Escherichia coli. [europepmc]
• Treatment Options for Colistin Resistant Klebsiella pneumoniae : Present and Future. [europepmc]
• The Role of fosA in Challenges with Fosfomycin Susceptibility Testing of Multispecies Klebsiella pneumoniae Carbapenemase-Producing Clinical Isolates. [europepmc]
• Antibiotic Resistance Among Uropathogenic Escherichia coli . [europepmc]
• The Clinical Significance of High Antimicrobial Resistance in Community-Acquired Urinary Tract Infections. [europepmc]
• Performance of Four Fosfomycin Susceptibility Testing Methods against an International Collection of Clinical Pseudomonas aeruginosa Isolates. [europepmc]
• Susceptibility of Clinical Isolates of Escherichia coli to Fosfomycin as Measured by Four In Vitro Testing Methods. [europepmc]
• The Five Ds of Outpatient Antibiotic Stewardship for Urinary Tract Infections. [europepmc]
• Use of Fosfomycin Etest To Determine In Vitro Susceptibility of Clinical Isolates of Enterobacterales Other than Escherichia coli, Nonfermenting Gram-Negative Bacilli, and Gram-Positive Cocci. [europepmc]
• Differences in Fosfomycin Resistance Mechanisms between Pseudomonas aeruginosa and Enterobacterales . [europepmc]
• The antimicrobial peptide DGL13K is active against drug-resistant gram-negative bacteria and sub-inhibitory concentrations stimulate bacterial growth without causing resistance. [europepmc]
• Fosfomycin Disk Diffusion Testing among Klebsiella pneumoniae Results in Frequent Inner Colonies and Categorical Disagreement Based on Conflicting Breakpoint Organization Recommendations. [europepmc]
• Performance Evaluation of BD Phoenix and MicroScan WalkAway Plus for Determination of Fosfomycin Susceptibility in Enterobacterales . [europepmc]
• Efficacy of antibiotic combinations in an experimental sepsis model with Pseudomonas aeruginosa. [europepmc]
• Characterizing carbapenemase-producing Escherichia coli isolates from Spain: high genetic heterogeneity and wide geographical spread. [europepmc]
• Skipped wells and scientific error during fosfomycin agar dilution and broth microdilution lead to inconsistent minimal inhibitory concentrations and may be cause for reevaluating testing methods for Klebsiella pneumoniae . [europepmc]
• Evaluation of several routine methods for fosfomycin and mecillinam susceptibility testing of Enterobacterales urine isolates. [europepmc]
• Heteroresistance associated with the production of fosfomycin-resistant inner colonies during disk diffusion testing among a geographically diverse collection of Klebsiella pneumoniae clinical isolates. [europepmc]
• Clinical Predictors and Pathogen Resistance Dynamics in Hospitalized Patients with Urinary Tract Infections: A 2025 Institutional Study. [europepmc]